- Home
- NCTY vs FBIO Comparison
NCTY vs FBIO Comparison
Compare NCTY & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCTY | FBIO |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | China | United States |
| Employees | N/A | 101 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.8M | 104.6M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | NCTY | FBIO |
|---|---|---|
| Price | $5.23 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 20.0K | ★ 382.1K |
| Earning Date | 03-27-2015 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $1.33 |
| 52 Week High | $15.98 | $4.53 |
Technical Indicators
Market Signals| Indicator | NCTY | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 42.72 | 37.28 |
| Support Level | $5.02 | $2.42 |
| Resistance Level | $7.22 | $4.05 |
| Average True Range (ATR) | 0.56 | 0.15 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 13.74 | 23.53 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.